{"preliminary_commentary":{"by_channel":{"youtube":62,"x_thread":43,"podcast":37},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03329690\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-10T02:51:17.013Z","note":"Automated from the 40 newest of 142 indexed sources (Oct 2021 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether HER2 status must be re-biopsied after trastuzumab progression before starting T-DXd\n- Whether T-DXd has meaningful activity in HER2-low IHC 2+/ISH− or IHC 1+ gastric cancer\n- Whether findings from an East Asian third-line population apply to Western patients\n- Whether baseline HER2 level and MET, EGFR or FGFR2 alterations predict response to T-DXd","kind":"questions"},"drugs_tested":[["trastuzumab deruxtecan"]],"indication":"HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma","name":"DESTINY-Gastric01","nct_id":"NCT03329690","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-gastric01-nct03329690. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.","label":"Parallel: DS-8201a","type":"EXPERIMENTAL"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.","label":"Parallel: Physician's Choice","type":"ACTIVE_COMPARATOR"},{"description":"A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.","label":"Exploratory: Naïve HER2 IHC 2+/ISH-","type":"OTHER"},{"description":"A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.","label":"Exploratory: Naïve HER2 IHC 1+","type":"OTHER"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2020-12-11","type":"ACTUAL"},"conditions":["Neoplasm, Gastrointestinal"],"enrollment":{"count":233,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"DS-8201a","otherNames":["Experimental product"],"type":"DRUG"},{"name":"Physician's Choice","otherNames":["Standard of Care"],"type":"DRUG"}],"last_update":"2022-03-18","lead_sponsor":"Daiichi Sankyo Co., Ltd.","official_title":"A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2019-11-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Objective Response Rate Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)","timeFrame":"Baseline to date of first documented objective response (CR or PR), up to 36 months postdose"},{"measure":"Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)","timeFrame":"Baseline to date of first documented objective response, up to 36 months postdose"}],"references":[{"citation":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29.","pmid":"32469182","type":"RESULT"},{"citation":"Kapil A, Failmezger H, Fu Y, Spitzmuller A, Chan J, Haneder S, Shumilov A, Barkell A, Oguma T, Inaki K, Suto F, Allard J, Lee J, Lambert AW, Schick M, Barrett JC, Schmidt G, Sade H, Gustavson M, Carroll D, Cecchi F. Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer. JCO Precis Oncol. 2026 May;10(5):e2500823. doi: 10.1200/PO-25-00823. Epub 2026 May 28.","pmid":"42208007","type":"DERIVED"},{"citation":"Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15.","pmid":"36379002","type":"DERIVED"}],"start_date":{"date":"2017-11-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]","url":"https://clinicaltrials.gov/study/NCT03329690"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-gastric01-nct03329690"}